XML 60 R44.htm IDEA: XBRL DOCUMENT v3.25.4
General (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Nov. 13, 2025
Jul. 15, 2024
Mar. 15, 2024
Oct. 29, 2019
Oct. 28, 2019
Jan. 31, 2026
Dec. 31, 2025
Dec. 31, 2024
Feb. 25, 2025
General [Line Items]                  
Percentage of shares issued and outstanding       65.00%          
Accumulated deficit             $ (216,896) $ (180,697)  
Goodwill               801  
Amount of goodwill               300  
Percentage of discount for lack of marketability             9.40%    
Goodwill impairment             801  
IPR&D impairment             11,842 3,237  
Long-lived assets             1,653 $ 4,046  
Merger Warrants [Member]                  
General [Line Items]                  
Warrants purchase (in Shares)     11,403           366,087
IPR&D [Member]                  
General [Line Items]                  
Intangible assets             15,287    
Goodwill             $ 501    
Common Stock [Member]                  
General [Line Items]                  
Number of shares received (in Shares)         10,527   148,857 [1],[2]    
Reverse stock split 1-for-19                
Aggregate shares issued (in Shares)     48,237         48,237 [1],[2]  
Warrants purchase (in Shares)     11,403            
Number of shares converted (in Shares)   574,484         1,174    
Merger Agreement [Member]                  
General [Line Items]                  
Owned percentage             55.00%    
Transaction costs               $ 888  
APT Stockholders [Member]                  
General [Line Items]                  
Owned percentage             45.00%    
BiomX Israel [Member]                  
General [Line Items]                  
Number of shares received (in Shares)       79,311          
Adaptive Phage Therapeutics LLC [Member]                  
General [Line Items]                  
Goodwill impairment             $ 801    
IPR&D impairment             3,237    
Long-lived assets             $ 4,046    
Subsequent Event [Member]                  
General [Line Items]                  
Funds raised           $ 3,000      
Redeemable Convertible Preferred Stock [Member]                  
General [Line Items]                  
Aggregate shares issued (in Shares)     40,470            
Number of shares converted (in Shares)   109,152 6       223    
Percentage of discount for lack of marketability             14.90%    
[1] All share amounts have been retroactively adjusted to reflect a 1-for-19 reverse share split as discussed in Note 12A.
[2] See note 12A.